Regeneron Pharmaceuticals (REGN) Research & Development (2009 - 2026)

Regeneron Pharmaceuticals' Research & Development history runs 18 years deep, the most recent figure standing at $1.5 billion for Q1 2026.

• In Q1 2026, Research & Development rose 16.28% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $6.1 billion (up 16.41% YoY), while the FY2025 annual figure was $5.9 billion, up 13.99% from the prior year.
• Research & Development was $1.5 billion for Q1 2026 at Regeneron Pharmaceuticals, down from $1.6 billion in the prior quarter.
• In the past five years, Research & Development ranged from a high of $1.6 billion in Q4 2025 to a low of $794.3 million in Q2 2022.
• Historically, Research & Development has averaged $1.2 billion across 5 years, with a median of $1.2 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Research & Development jumped 41.42% in 2022, then rose 6.33% in 2025.
• A 5-year view of Research & Development shows it stood at $1.0 billion in 2022, then gained by 12.86% to $1.2 billion in 2023, then climbed by 19.95% to $1.4 billion in 2024, then rose by 15.15% to $1.6 billion in 2025, then fell by 5.08% to $1.5 billion in 2026.
• The last three Research & Development figures came in at $1.5 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.5 billion (Q3 2025), per Business Quant data.